Table 1 Patient demographics and baseline disease characteristics
1 Prior line | ⩾2 Prior lines | |||
|---|---|---|---|---|
Kd (n=232) | Vd (n=232) | Kd (n=232) | Vd (n=233) | |
Age, median years (range) | 66.0 (36.0–89.0) | 63.5 (39.0–88.0) | 64.0 (35.0–89.0) | 66.0 (30.0–86.0) |
ECOG PS, n (%) | ||||
0 | 110 (47.4) | 131 (56.5) | 111 (47.8) | 101 (43.3) |
1 | 104 (44.8) | 92 (39.7) | 107 (46.1) | 111 (47.6) |
2 | 18 (7.8) | 9 (3.9) | 14 (6.0) | 21 (9.0) |
Cytogenetic risk by FISH at study entry, n (%) | ||||
High risk | 44 (19.0) | 53 (22.8) | 53 (22.8) | 60 (25.8) |
Standard risk | 149 (64.2) | 144 (62.1) | 135 (58.2) | 147 (63.1) |
Unknown/missing | 39 (16.8) | 35 (15.1) | 44 (19.0) | 26 (11.1) |
Creatinine clearance, n (%) | ||||
<30 ml/min | 14 (6.0) | 17 (7.3) | 14 (6.0) | 11 (4.7) |
30 to <50 ml/min | 26 (11.2) | 27 (11.6) | 31 (13.4) | 44 (18.9) |
50 to <80 ml/min | 97 (41.8) | 85 (36.6) | 89 (38.4) | 92 (39.5) |
⩾80 ml/min | 95 (40.9) | 103 (44.4) | 98 (42.2) | 86 (36.9) |
ISS stage, n (%) | ||||
Stage 1 | 109 (47.0) | 115 (49.6) | 103 (44.4) | 90 (38.6) |
Stage 2 | 68 (29.3) | 62 (26.7) | 70 (30.2) | 89 (38.2) |
Stage 3 | 55 (23.7) | 55 (23.7) | 59 (25.4) | 54 (23.2) |
Prior therapy, n (%) | ||||
Bortezomib | 96 (41.4) | 101 (43.5) | 154 (66.4) | 151 (64.8) |
Lenalidomide | 51 (22.0) | 47 (20.3) | 126 (54.3) | 130 (55.8) |
